Novo, Pfizer Are Battling To Buy The Future Of Weight-Loss — But Viking Already Owns It

Pfizer Inc's (NYSE:PFE) lawsuit. Novo Nordisk A/S' (NYSE:NVO) counterbid. And in the middle of it all — a quiet $45 million position that might turn into Andreas Halvorsen's next masterstroke. After years of fighting from the sidelines of the Ozempic boom, Pfizer is finally throwing punches. Pfizer is suing obesity-drug developer Metsera Inc (NASDAQ:MTSR) to block a takeover by Novo Nordisk. The war between the two pharma giants is driving MTSR stock higher, Wednesday.Track MTSR stock here.But while the pha ...